China NMPA Approved Anniko® (Penpulimab) for First-line Treatment of Locally Advanced or Metastatic Squamous NSCLC ...Middle East

HONG KONG, Jan. 15, 2023 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso"), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, announced that the anti PD-1 monoclonal antibody drug Anniko®...

Hence then, the article about china nmpa approved anniko penpulimab for first line treatment of locally advanced or metastatic squamous nsclc was published today ( Monday 16/01/2023 - 04:04 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( China NMPA Approved Anniko® (Penpulimab) for First-line Treatment of Locally Advanced or Metastatic Squamous NSCLC )

Also on site :

• Iranian Foreign Minister spokesperson in exclusive interview discusses cause of the war and Iran’s stance
• Walmart’s 'Very Sturdy' $53 3-Piece Patio Set Is Perfect for Small-Space Entertaining
• ‘Inflationary surge’: Fed economists warn AI hype is overheating the economy whether or not the technology ever delivers